Today, Sagitta Biotech announced positive preclinical results for its Flu vaccine candidate, demonstrating robust immunogenicity and efficacy in mice. These findings represent a significant development milestone and support advancement towards clinical trials. The company is currently moving to complete a significant Series A (2027) to finance its next stage of development.
“Our team is thrilled by the strength and consistency of these data,” said Dr. Benjamin DAMIEN, Chief Executive Officer of Sagitta Biotech. “This milestone validates our scientific approach and brings us closer to delivering a transformative therapy to patients”.
Key preclinical highlights:
- Demonstrated good immunogenicity and 90% mice survival in challenge studies
- Scalable, reproducible manufacturing process established to support next development phases
“These results underscore the biological rationale and translational potential of our candidate,” added Dr. Hélène GAZON, Chief Scientific Officer. “We are now focused on finalizing analytical and manufacturing steps and preparing for our next development phases.”
Next steps:
- Complete CMC (Chemistry, Manufacturing, and Controls) activities to validate the platform
- Engage with regulators to align on first-in-human study design, to prepare for Ph1 clinical trials
- Complete proof of concept of other indications to demonstrate the flexibility of the platform
Sagitta’s vaccine R&D program is supported by non-dilutive funding provided by SPW Economie Emploi Recherche.
About Sagitta Biotech
Sagitta Biotech is a biotechnology company developing innovative vaccines, leveraging proprietary hybrid platform (viral vectors/mRNA technologies) to address high unmet medical needs. Its technology is able to deliver quickly safe and effective vaccines, produced from a constant manufacturing process. This translates into fast and cost-effective vaccine development. Beyond the development of vaccines, Sagitta is also expanding its pipeline to targeted therapies for indications in oncology and autoimmune diseases. Sagitta will also be moving soon to larger R&D facilities in the GIGA enterprise building, close to Liège University Hospital (CHU).
For more information, visit www.sagittabiotech.com
Media Contact: Benjamin DAMIEN, CEO – Sagitta Biotech: b.damien@sagittabiotech.com
Forward-Looking Statements: This press release contains forward-looking statements, including statements regarding development plans, regulatory timelines, and clinical initiation. Actual results may differ materially due to risks and uncertainties, including preclinical, regulatory, manufacturing, and clinical factors. Sagitta Biotech undertakes no obligation to update these statements except as required by law.
